NasdaqGM - Nasdaq Real Time Price USD

Ikena Oncology, Inc. (IKNA)

1.1400
+0.0100
+(0.88%)
At close: May 12 at 4:00:01 PM EDT
1.1400
0.00
(0.00%)
After hours: May 12 at 4:00:10 PM EDT
Loading Chart for IKNA
  • Previous Close 1.1300
  • Open 1.1450
  • Bid --
  • Ask --
  • Day's Range 1.1250 - 1.2424
  • 52 Week Range 0.9710 - 1.9400
  • Volume 37,025
  • Avg. Volume 93,543
  • Market Cap (intraday) 55.014M
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0200
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.00

Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

ikenaoncology.com

10

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IKNA

View More

Performance Overview: IKNA

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IKNA
30.49%
S&P 500 (^GSPC)
0.64%

1-Year Return

IKNA
11.63%
S&P 500 (^GSPC)
11.90%

3-Year Return

IKNA
69.52%
S&P 500 (^GSPC)
48.70%

5-Year Return

IKNA
94.91%
S&P 500 (^GSPC)
103.62%

Compare To: IKNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IKNA

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    54.53M

  • Enterprise Value

    -62.33M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.43

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.44%

  • Return on Equity (ttm)

    -33.30%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -49.23M

  • Diluted EPS (ttm)

    -1.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    124.39M

  • Total Debt/Equity (mrq)

    5.97%

  • Levered Free Cash Flow (ttm)

    -31.55M

Research Analysis: IKNA

View More

Company Insights: IKNA

Research Reports: IKNA

View More

People Also Watch